Revolution Medicines, Inc. Warrant (RVMDW)
RVMDW Stock Price Chart
Explore Revolution Medicines, Inc. Warrant interactive price chart. Choose custom timeframes to analyze RVMDW price movements and trends.
RVMDW Company Profile
Discover essential business fundamentals and corporate details for Revolution Medicines, Inc. Warrant (RVMDW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Feb 2020
Employees
616.00
Website
https://www.revmed.comCEO
Mark A. Goldsmith
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
RVMDW Financial Timeline
Browse a chronological timeline of Revolution Medicines, Inc. Warrant corporate events including earnings releases, dividend announcements, and stock splits.
RVMDW Stock Performance
Access detailed RVMDW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.